Original Research Paper

Rapid and effective treatment of traumatic spinal cord injury using stem cell derived exosomes

Jiafu Mu\textsuperscript{a}, Jiahe Wu\textsuperscript{a}, Jian Cao\textsuperscript{a}, Teng Ma\textsuperscript{a}, Liming Li\textsuperscript{a,b,∗}, Shiqing Feng\textsuperscript{c,d}, Jianqing Gao\textsuperscript{a,e,∗}

\textsuperscript{a}College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China
\textsuperscript{b}Pilot National Laboratory for Marine Science and Technology, Qingdao 266137, China
\textsuperscript{c}Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
\textsuperscript{d}International Science and Technology Cooperation Base of Spinal Cord Injury, Tianjin Key Laboratory of Spine and Spinal Cord Injury, Department of Orthopedics, Tianjin Medical University General Hospital, Tianjin 300052, China
\textsuperscript{e}Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cell and Regenerative Medicine, Zhejiang University, Hangzhou 310058, China

\section*{A R T I C L E  I N F O}

Article history:
Received 20 March 2021
Revised 21 October 2021
Accepted 21 October 2021
Available online 29 October 2021

Keywords:
Exosome
Fibrin glue
Spinal cord injury
Emergency treatment

\section*{A B S T R A C T}

Traumatic spinal cord injury is a fatal acute event without effective clinical therapies. Following the trauma, immediate neural protection and microenvironment mitigation are vital for nerve tissue repair, where stem cell-based therapies could be eclipsed by the deficiency of cells due to the hostile microenvironment as well as the transport and preservation processes. Effective emergency strategies are required to be convenient, biocompatible, and stable. Herein, we assess an emergency cell-free treatment using mesenchymal stem cell-derived exosomes, which have proven capable of comprehensive mitigation of the inhibitory lesion microenvironment. The clinically validated fibrin glue is utilized to encapsulate the exosomes and in-situ gelates in transected rat spinal cords to provide a substrate for exosome delivery as well as nerve tissue growth. The emergency treatment alleviates the inflammatory and oxidative microenvironment, inducing effective nerve tissue repair and functional recovery. The therapy presents a promising strategy for effective emergency treatment of central nervous system trauma.

© 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)

1. Introduction

As a trauma in the central nervous system (CNS), traumatic spinal cord injury (SCI) is among the most fatal diseases. Since there is a lack of clinically available therapy for effective nerve tissue repair and functional recovery, SCI has become one of the leading causes of adult death and disability [1,2]. Following the acute event, progressive secondary injury develops rapidly and continuously expands the damage to adjacent nerve tissues [2]. Correspondingly, an extremely hostile microenvironment grows in the injured spinal cord, involving

\textsuperscript{∗} Corresponding authors.
E-mail addresses: lmli@qnlm.ac (L.M. Li), gaojianqing@zju.edu.cn (J.Q. Gao).
Peer review under responsibility of Shenyang Pharmaceutical University.

https://doi.org/10.1016/j.ajps.2021.10.002
1818-0876/© 2021 Shenyang Pharmaceutical University. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
severe inflammation and oxidative stress, and impedes nerve recovery both from intrinsic and therapeutic approaches [3,4]. Prompt administration straightly after the acute trauma is vitally important to dispute the inhibitory parameters and patch the substrate, thus preserving neurons and promoting tissue repair [5,6]. The crucial role of the management in the immediate post-injury phase has been emphasized by studies showing increased risk of secondary complications posed by the failure to access emergency treatments [6,7]. However, almost every trauma occurs remotely from medical facilities. In consequence, there is an urgent need for emergency treatment with feasible and biocompatible intervention to the lesion microenvironment within the initial stage of the devastating acute event.

Stem cell transplantation has proven promising for nerve tissue regeneration in extensive studies [8–11], especially for mesenchymal stem cells (MSCs), of which the therapeutic effects are mainly attributed to the microenvironment mitigation functions by cellular paracrine [12–14]. However, cell-based therapies could be largely eclipsed by the preservation and transportation procedures as well as the hostile lesion microenvironment [10]. As vehicles of paracrine secretions, exosomes hold great promise in medical treatments. MSC-derived exosomes have been demonstrated to mitigate the SCI microenvironment and promote nerve repair [15–17]. Hence, instead of stem cells, exosomes represent more qualified candidates for emergency treatment of acute SCI. And among the alternative cell sources, human umbilical cord MSCs are clinically accessible and extensively applied in experimental therapies. Therefore, exosomes are isolated from the MSCs in this study and evaluated for emergency treatment of SCI.

On the other hand, due to the damage of extracellular matrix (ECM) in the lesion site, the emergency intervention still requires a biocompatible substrate to provide an immediate supplement for ECM as well as efficient delivery of the exosomes [18]. Vector materials for exosome transplantation in nerve tissues are poorly demonstrated. Viscoelastic hydrogels mimic the ECM of soft nerve tissues, among which injectable hydrogels could meet the demand of simple and rapid operation in emergency care. Our previous study has reported effective nerve tissue regeneration and functional restoration by a transplantation strategy based on a hyaluronic acid hydrogel and human MSC-derived exosomes [17]. Herein, fibrin glue, a clinically validated injectable hydrogel, is applied to encapsulate the transplanted exosomes. The in-situ formation of fibrin glue mimics the blood clotting process, utilizing fibrinogen and thrombin from natural human blood as the two gelation constituents. Fibrin glue is extensively used in clinical practices and has been approved for its biocompatibility and wound healing properties, but rarely used in SCI medical treatment due to the absence of effective SCI therapy. In this study, the transplantation of the exosome-encapsulated fibrin glue (FG-Exo) is designed as a feasible emergency treatment to comprehensively mitigate the SCI microenvironment. Significant functional recovery and nerve tissue repair are induced by the emergency treatment, which could be possibly attributed to the attenuation of inflammatory and oxidative responses. The exosome-based strategy in the current study showed promising results in the animal study and yielded potential for translation in human SCI.

2. Materials and methods

2.1. Materials

Minimum essential medium-α (MEM-α) was purchased from Biological Industries (Beit Haemek, Israel). The human basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) were purchased from Pepro Tech Group (New Jersey, USA). Fetal bovine serum (FBS) and 0.25% (w/v) trypsin were purchased from Gibco BRL (Gaithersburg, MD, USA). Human umbilical cord mesenchymal stem cells were obtained from Ever Union Biotechnology (Beijing, China). Fibrinogen and thrombin were purchased from Shanghai RAAS Blood Products Co., Ltd. (Shanghai, China). Female SD rats weighing about 230 g were purchased from SLAC Laboratory Animal Co., Ltd. (Shanghai, China). All animal procedures and experiments were approved by the Institutional Animal Care and Use Committee at Zhejiang University.

2.2. Culture of human umbilical cord MSCs and exosome isolation

The culture medium for MSCs derived from the human umbilical cord was prepared using MEM-α supplemented with 10% FBS and human-derived factors bFGF and EGF both at 20 ng/ml. The cells were cultured in 37 °C and 5% CO₂ atmosphere, and the medium was refreshed every two days. The culture supernatant was collected and centrifuged at 3,000 g and 10,000 g for 30 min, respectively, to remove cell debris. Then, after ultrafiltration at 2,000 g for 8 min using Amicon-ultra (100 kD, Millipore, USA), the supernatant was ultracentrifuged at 100,000 g and 4 °C for 70 min to obtain the exosome pellet. The exosomes were suspended in PBS at -80 °C before use.

2.3. Characterization of exosomes

The collected exosomes were detected by transmission electron microscope (TEM) (JEM-1200EX, JEOL, Japan). Formvar/carbon-coated 200-mesh copper electron microscopy grids were loaded with exosome suspension of 5 μl through incubation for 1 min at room temperature. Then, the grids were stained with standard uranyl acetate and semi-dried for TEM observation. The exosomes were examined for expression of CD9 and CD63 by Western blotting assay. Exosome suspensions were lysed and incubated for 5 min at 95 °C. The sample was centrifuged and examined in Jess Simple Western System (Bio-technie, Minneapolis, USA) using CD9 (OM198821, Omnimabs, CA, USA) and CD63 antibodies (OM245783, Omnimabs, CA, USA). The distribution of the exosome diameters was examined by nanoparticle tracking analysis (NTA) using the NanoSight NS300 system. Before using in the experiment, the exosomes were quantified according to the protein content by Micro-BCA Protein Assay (23235, Thermo Fisher Scientific, USA).
2.4. Fibrin glue fabrication and encapsulation of exosomes

Fibrinogen (1.5 mg) was dissolved in ultrapure water (30 μl) to obtain a fibrinogen solution of 50 mg/ml. Thrombin was dissolved in CaCl₂ solution at a concentration of 500 IU/ml. The solutions were mixed at an equal volume of 30 μl to form a 60 μl fibrin glue. The hydrogel was dehydrated, fractured, and coated with gold for observation using scanning electron microscope (SEM) (SU8010, Hitachi, Japan). For exosome-encapsulated fibrin glue (FG-Exo), before gelation, the solutions of fibrinogen and thrombin were prepared at a two-fold concentration and then respectively mixed, at equal volumes, with exosome suspension containing 50 μg of exosomes in 15 μl. Finally, the density of exosomes in fibrin glue was 100 μg/60 μl.

2.5. Detection of exosomes in fibrin glue

Exosomes were fluorescently labeled through incubation with the CM-Dil (40718ES50, Yeasen, Shanghai, China) at a 2 μg/ml concentration of the dye at 37 °C for 5 min and subsequently 4 °C for 15 min. After ultracentrifugation at 100 000 g for 70 min at 4 °C to remove the excess dye, the labeled exosomes were encapsulated in fibrin glue as mentioned above. The fibrin glue was observed in a confocal laser scanning microscope (CLSM), and exosomes distributed in the gel were detected by z-stack scanning.

2.6. Spinal cord transection and FG-Exo treatment

Female SD rats weighing around 230 g were randomly separated into four groups with 6 animals in each. Animals received spinal cord transection surgery under deep anesthesia as reported previously [4]. Briefly, the hair on the back near T10 was removed and the muscle was separated. Laminectomy was conducted to expose the dorsal surface of T9 to T11 segment. The spinal cord was transected at T9 to T10, leaving a lesion gap of 4~5 mm. After exact hemostasis, the fibrinogen and thrombin solutions containing exosomes each of 30 μl were injected into the lesion site simultaneously (FG-Exo group). And blank fibrin glue was formed in the lesion site through injection of exosome-free fibrinogen and thrombin (FG group). Non-treated control termed as SCI group was injected with the same volume of PBS. Animals receiving laminectomy without spinal cord transection served as the Sham group. Finally, after suture of the muscle and skin, the animals were kept warm until recovery from the anesthesia. The animals received penicillin within 7 d post-surgery. Manual bladder massage was performed for postsurgical care twice daily until the reflexive bladder activity returned.

2.7. Evaluation of motor function restoration

Locomotor function evaluation was conducted by a Basso, Beattie, Bresnahan (BBB) locomotion rating scale and a horizontal ladder rung walking test. For BBB assessment, the rats were tested weekly after the surgery in an open field by observers blinded to the treatment groups. The behavioral outcomes were evaluated by the 21-pointed rating scale. A ladder rung walking test was conducted by allowing the rats to walk from one to the other end of a horizontal ladder with irregular distance arrangements between the rungs. The walking ability was evaluated according to the placement of the limbs during stepping. The tests were recorded by a camera. Effective steps in the ladder were defined as pedal activities of the hind limb against the metal rungs. The outcome was analyzed by GraphPad prism 8.0.

2.8. Tissue processing and immunohistochemistry

At 4-week post-surgery, animals were perfused under deep anesthesia by isotonic physiological saline, and tissues of the spinal cord, heart, liver, spleen, lung, kidney, and bladder were harvested. For immunofluorescence staining of the spinal cord, after fixation in 4% paraformaldehyde in PBS for 24 h, the tissue was dissected to collect a 1.5 cm segment encompassing the lesion site and dehydrated by 30% sucrose. The sample was then embedded in an optimal cutting temperature compound (OCT) (Thermo Fisher, USA) and cryosectioned into 20 μm thick slices. The sections were stained for interested markers through incubation with primary antibodies of glial fibrillary acidic protein (GFAP) (BA0056, Boster, Wuhan, China), neurofilament (NF) (#2836, Cell Signaling Technology, USA), 4-hydroxynonenal (4-HNE) (AB46545, Abcam, USA), 8-hydroxy-2′-deoxyguanosine (8-OHdG) (OM176273, Omnibio, The Netherlands), 8-hydroxy-2′-deoxyguanosine (8-OHdG) (OM176273, Omnibio, USA), 8-hydroxy-2′-deoxyguanosine (8-OHdG) (OM176273, Omnibio, USA), and myelin basic protein (MBP) (OM264373, Omnibio, USA) overnight at 4 °C, then after washing, with fluorescence conjugated secondary antibodies (34206ES60, 34106ES60, 34212ES60, 34112ES60, Jackson ImmunoResearch, USA) at 37 °C for 1 h. The sections were finally stained with DAPI (62248, Invitrogen, USA). For other tissues, after fixation in 10% neutral formalin, the tissues were trimmed, dehydrated, and paraffin-embedded. Paraffin slices of 4 μm were prepared for hematoxylin and eosin (HE) (G1120, Beijing Solarbio Science & Technology, China) and Masson staining (G1346, Beijing Solarbio Science & Technology, China) by using the assay kits.

2.9. Statistical analysis

Quantitative analysis of immunohistochemistry results was processed using ImageJ 1.52n. The data were shown as mean ± standard deviation (SD) values. Statistical analysis was performed by GraphPad prism 8.0 using the one-way ANOVA test.

3. Results and discussion

3.1. Exosome encapsulation in fibrin glue

MSCs derived from the human umbilical cord were cultured in vitro, and the exosomes were isolated from the cell
culture supernatant. The exosomes were observed in TEM and showed cup-shaped morphologies around 100–200 nm (Fig. 1A). The exosome particles were further detected by NTA, revealing most particles were about 150 nm (Fig. 1B). CD63 and CD9 are two surface markers on the membrane of exosomes. Expression of the proteins analyzed by Western blot assay (Fig. 1C) suggested successful isolation of the exosomes. To make efficient delivery of the exosomes during transplantation and provide biocompatible ECM to the lesion site, the strategy applied fibrin glue, a clinically validated in situ hydrogel. Solutions of fibrinogen and thrombin were mixed to form the fibrin glue. The gel was dehydrated and detected by SEM, which showed a highly porous three-dimensional (3D) structure with nanofibers (Fig. 1D). MSC-derived exosomes were suspended in the gel solutions to construct exosome-encapsulated fibrin glue. Encapsulation of exosomes showed no obvious difference in gelation of fibrin glue. Exosomes labeled by CM-Dil were observed in the fibrin glue and exhibited a high-density 3D spatial distribution (Fig. 1E).

3.2. Nerve tissue repair by the emergency treatment

The treatment strategy was subsequently evaluated in a rat spinal cord transection model (Fig. 2A). After transection injury of the spinal cord, the exosome-suspended fibrinogen and thrombin solutions were synchronously injected into the lesion site and allowed for gelation (FG-Exo group). PBS (SCI group) and blank fibrin glue (FG group) treatments served as controls. According to BBB score assessment, rats without effective treatment after the acute injury failed to obtain functional recovery and exhibited almost total paralysis during the whole post-injury period (Fig. 2B). The emergency therapy using fibrin glue-encapsulating exosomes effectively promoted recovery of hindlimb motor functions, indicating a significant advantage of the emergency treatment strategy over both the SCI and FG groups. The rats presented similar outcomes in the ladder running walking task, which has proven sensitive to movement disorders following an injury of the motor system in rat models of stroke and SCI [19]. The FG-Exo group exhibited more effective steps on the ladders of about 30% compared to those lower than 10% in the other two groups (Fig. 2C). The performance of rats in BBB (Videos S1–S4) and ladder tests (Videos S5) were recorded by videos. The motor function outcomes suggested a promising role of the emergency treatment strategy using FG-Exo and predicted the effects of the therapy on nerve tissue regeneration. Nerve tissue regenerative effects of the FG-Exo emergency treatment were further evaluated (Fig. 2D–Fig. 2F, Fig. S1A). As for indicators of mature neurons and astrocytes in glial scars respectively, NF and GFAP were considered correlatedly indicating the nerve tissue regeneration extent [20,21]. The
FG-Exo treated tissue exhibited reduced lesion volume and increased integrity, with a more abundant distribution of NF in both the lesion and adjacent areas. Investigation of ChAT and MBP showed similar results among the groups (Fig. S2). FG-Exo treated tissue obtained significantly increased extensive distribution of ChAT, an indicator for cholinergic neurons. And the recovery of MBP in the lesion site also indicated improved remyelination in the FG-Exo group compared to both SCI and FG groups.

By using the clinical materials, human umbilical cord MSCs and fibrin glue, the strategy elicited significant nerve repair effects. In the experiment, the therapy was performed following the injury of spinal cord transection. The in-situ formed 3D system serves as a biocompatible ECM containing comprehensive microenvironment regulators. The functional restoration, indicated by BBB scores and ladder rung walking test, showed an obvious advantage of the composite system over the blank fibrin glue. On the other hand, however, this effect is inferior to several previous studies of the authors using other functional materials and stem cells [4,17,22]. More studies, especially clinical translation, of superior functional biomaterials are crucial to develop effective emergency treatments. And the dosage of transplanted exosomes remains to be optimized in further investigations. Besides, the introduction of anti-inflammatory and antioxidant drugs in the system could...
also contribute to protecting the nerve tissue in the acute phase.

3.3. Mitigation of microenvironment

After the acute trauma, extensive secondary damage occurs in the spinal cord tissue, involving ischemia, severe oxidative stress, and inflammatory responses [23]. Exosomes derived from MSCs have been reported to alleviate inhibitory environment and secondary injury. Especially, our previous research has reported the promotive effects of exosomes derived from the human placental amniotic membrane MSCs in SCI therapy [17]. In the current study, stem cell-derived exosomes are delivered by fibrin glue in order to comprehensively regulate the microenvironment via mitigating inhibitory factors and supplementing substrates, which are vitally important for the protection of neurons during the acute phase [24,25]. Herein, the emergency treatment using FG-Exo was also further evaluated for the effects on the lesion microenvironment. Excessive production of ROS lastingly causes damage to the nerve tissues [26,27], leaving 4-HNE and 8-OHdG as markers of tissue peroxidative damage. Detection of the two markers showed obviously more extensive distribution of the peroxidative damage products in the lesion of SCI group, while administration with FG and FG-Exo effectively prevented the oxidative procedures (Fig. 3, Fig. S1B-S1C). This result was especially significant for the lipid peroxidation indicated by 4-HNE analysis (Fig. 3C).

On the other hand, inflammation is a leading cause of neural damage. Macrophages were detected for both M1
and M2 phenotypes, which proved opposite impacts in inflammation. Examination and colocalization of CD68 and iNOS suggested more distribution of pro-inflammatory M1 macrophages in the SCI and blank FG group than the FG-Exo group (Fig. 4A, Fig. S3A-S3B). The overexpression of iNOS also intensified the inflammatory progression and neuron degeneration after injury [24]. A more obvious difference was exhibited in the result of M2 macrophage detection (Fig. 4B, Fig. S3C and S3D), showing a significantly extensive distribution of Arg-1 positive M2 macrophages in FG-Exo treated spinal cord tissue. These results indicate the anti-inflammatory and neuronal protective effects of the FG-Exo emergency treatment. The exosomes elicited significant anti-inflammatory effects through regulation on macrophage phenotypes, which mechanism is inconsistent with previous reports about systemically administrated exosomes [15].

3.4. Urinary protection effect and safety of the FG-Exo treatment

Injury of spinal cord tissue always results in dysfunction of the urinary system. Urinary disorders cause irreversible damage in kidney and bladder tissues and are severe complications among SCI patients, even threatening their survival [28-30]. HE staining (Fig. 5A and S4A), as well as Masson staining (Fig. 5B and S4A) of the bladder tissues after a 4-week treatment, showed attenuation effect of the FG-Exo therapy on disorders in the bladder wall and the muscle bundle. Repair of spinal cord nerve tissues could restore urinary functions and alleviate neurogenic bladder. Therefore, urinary damage is a critical indicator of the nerve regeneration effect. The examinations of the bladder tissue damage revealed the urinary protective effects
of the emergency treatment by FG-Exo, suggesting the impact on spinal cord repair. More than that, there rises new aspirations in the current study. As mentioned above, the authors have evaluated the therapeutic functions of exosome transplantation in the previous study. Although the strategies and materials are quite different in the current study, significant effects on bladder tissues were exhibited by both two experiments, in which exosome encapsulation effectively relieved neurogenic bladders compared to the blank material groups. The exosome-based therapies also induced better bladder conditions than stem cell treatments in the same SCI model (data not shown). These results may prompt further investigation on the possible related mechanisms.

Damage of the ECM is an inhibitory parameter blocking nerve tissue regeneration, and supplement for ECM by biomaterials has been considered an important approach in SCI treatment. Herein, the FG group was able to obtain slight extents of functional recovery and oxidative stress mitigation. This could be attributed to the tissue bridging effect of fibrin glue, which is also a basis for the application of the material to deliver exosomes. But the overall microenvironment mitigation effects in the FG group were significantly insufficient compared to those in the FG-Exo group (Figs. 3 and 4), especially for the anti-inflammatory effects (Fig. 4). Also, the therapeutic outcomes including the performance in open field walking and horizontal ladder rung walking (Fig. 2), and the urinary bladder conditions (Fig. 5), further proved the advantages of FG-Exo over FG.

The safety of this emergency therapy was evaluated through the investigation of rat organs in addition to blood indicators for liver and kidney conditions. Treatment by FG-Exo poses no apparent effect on general tissues (Fig. 6). Detection of tissues including the heart, liver, spleen, lung, and kidney showed consistent morphologies among all the experiment groups (Fig. 6A, Fig. S4B). The indexes in the serum for liver and kidney damages, including alanine transaminase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN), and creatinine (CR), exhibited similar levels (Fig. 6B).

4. Conclusion

Timely access to skilled management in the acute phase of traumatic SCI is essential to restrain the secondary injury and is largely decisive for the final nerve recovery outcomes. SCI patients who failed to obtain acute management are accompanied with an increased risk of secondary complications, showing higher mortality and severity of complications [6,31]. Despite the awareness of the importance of emergency treatment in clinical SCI management, the development of effective emergency treatments remains in its infancy. In experimental studies, transplantation of stem cells with biomaterials has been considered promising in SCI therapy. But further efforts are needed to answer the strict requirements in cell viability and material compatibility when stem cell-based strategies are applied in urgent management after storage and transportation processes. Also, the transplanted cells usually exhibit significant death and deficiency in the acute lesion microenvironment. Recent evidence on the therapeutic effects of stem cell-derived exosomes lightens the development of emergency treatment...
for SCI. From the aspect of clinical practice, the current study is aimed to develop a feasible emergency treatment that involves clinical accessible cell sources, validated materials, facile operation, and effective functional nerve recovery. The proposed FG-Exo treatment is a relatively simple therapy with the injection of the exosome-encapsulated in-situ fibrin glue. The therapeutic system could be preserved and transported conveniently for pre-hospital management with the rapid operation.

In conclusion, the study demonstrates a facile and efficient therapeutic strategy based on MSC-derived exosomes and fibrin glue for effective emergency treatment of acute SCI. The FG-Exo treatment proved functional in mitigation of the oxidative and inflammatory microenvironment, thus eliciting superior impact on nerve tissue repair and urinary tissue protection in the rat severe transection SCI model. Exosome transplantation strategies and the vectors used were both poorly reported in SCI treatments. In this study, although relatively simple and rapid, the proposed strategy exhibited highly promising for effective SCI treatment in clinical application. Besides, clinically approved, human umbilical cord MSCs and fibrin glue represent accessible and biocompatible materials. Therefore, we report that the FG-Exo transplantation provides a promising and safe exosome-based strategy for emergency treatment of acute SCI.

Conflict of interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This work was financially supported by the National Key Research and Development Project of Stem Cell and Transformation Research (2019YFA0112100, 2019YFA0112102), National Natural Science Foundation of China (81973252, 81803451 and 81620108028). We thank the Center of Cryo-Electron Microscopy (CCEM), Zhejiang University for the technical assistance on Confocal Laser Scanning Microscopy.

Supplementary materials

Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.ajps.2021.10.002.

REFERENCES

[1] 2016 GBD. Traumatic Brain Injury and Spinal Cord Injury Collaborators. Global, regional, and national burden of traumatic brain injury and spinal cord injury, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019;18(1):56–87.

[2] Rubiano AM, Carney N, Chesnut R, Puyana JC. Global neurotrauma research challenges and opportunities. Nature 2015;527(7578):S193–7.

[3] Bellák T, Fekécs Z, Török D, Táncozs Z, Nemes C, Tészla Z, et al. Grafted human induced pluripotent stem cells improve the outcome of spinal cord injury: modulation of the lesion microenvironment. Sci Rep 2020;10(1):22414.

[4] Li L, Xiao B, Mu J, Zhang Y, Zhang C, Cao H, et al. A MnO2 nanoparticle-dotted hydrogel promotes spinal cord repair via regulating reactive oxygen species microenvironment and synergizing with mesenchymal stem cells. ACS Nano 2019;13(12):14283–93.

[5] Liu YS, Feng YP, Xie JX, Luo ZJ, Shen CH, Niu F, et al. A novel first aid stretcher for immobilization and transportation of spine injured patients. PLoS One 2012;7(7):e39544.

[6] Sharwood LN, Dhalival S, Ball J, Burns B, Flower O, Joseph A, et al. Emergency and acute care management of traumatic spinal cord injury: a survey of current practice among senior clinicians across Australia. BMC Emerg Med 2018;18(1):57.

[7] Todd NV, Skinner D, Wilson-MacDonald J. Secondary neurological deterioration in traumatic spinal injury: data from medicolegal cases. Bone Jt J 2015;97-B(4):527–31.

[8] Sahni V, Kessler JA. Stem cell therapies for spinal cord injury. Nat Rev Neuro 2010;6(7):363–72.

[9] Tzou O, Sugai K, Yamaguchi R, Tashiro S, Nagoshi N, Kohyama J, et al. Concise review: laying the groundwork for a first-in-human study of an induced pluripotent stem cell-based intervention for spinal cord injury. Stem Cells 2019;37(1):6–13.

[10] Chhabra HS, Sarda K. Clinical translation of stem cell based interventions for spinal cord injury - are we there yet? Adv Drug Deliv Rev 2017;120:41–9.

[11] Gong Z, Xia K, Xu A, Yu C, Wang C, Zhu J, et al. Stem cell transplantation: a promising therapy for spinal cord injury. Curr Stem Cell Res Ther 2020;15(4):321–31.

[12] Venneruso V, Rossi F, Villella A, Bena A, Forloni G, Vegliànese P. Stem cell paracrine effect and delivery strategies for spinal cord injury regeneration. J Control Release 2019;300:141–53.

[13] Luo Q, Zhang B, Kang D, Song G. Role of stromal-derived factor-1 in mesenchymal stem cell paracrine-mediated tissue repair. Curr Stem Cell Res Ther 2016;11(7):585–92.

[14] Kusuma GD, Carthew J, Lim R, Frith JE. Effect of the microenvironment on mesenchymal stem cell paracrine signaling: opportunities to engineer the therapeutic effect. Stem Cells Dev 2017;26(9):617–31.

[15] Lankford KL, Arroyo EJ, Nazimek K, Bryniarski K, Askernase PW, Kocsis JD. Intravenously delivered mesenchymal stem cell-derived exosomes target M2-type macrophages in the injured spinal cord. PLoS One 2018;13(1):e0190358.

[16] Huang JH, Yin XM, Xu Y, Xu CC, Lin X, Ye FB, et al. Systemic administration of exosomes released from mesenchymal stromal cells attenuates apoptosis, inflammation, and promotes angiogenesis after spinal cord injury in rats. J Neurotrauma 2017;34(24):3388–96.

[17] Li L, Zhang Y, Mu J, Chen J, Zhang C, Cao H, et al. Transplantation of human mesenchymal stem-cell-derived exosomes immobilized in an adhesive hydrogel for effective treatment of spinal cord injury. Nano Lett 2020;20(6):4298–305.

[18] Liu S, Xie YY, Wang B. Role and prospects of regenerative biomaterials in the repair of spinal cord injury. Neural Regen Res 2019;14(8):1352–63.

[19] Tran AP, Warren PM, Silver J. The biology of regeneration failure and success after spinal cord injury. Physiol Rev 2018;98(2):881–917.

[20] Brosius Lutz A, Barres BA. Contrasting the glial response to axon injury in the central and peripheral nervous systems. Dev Cell 2014;28(1):7–17.
[21] Davies SJ, Fitch MT, Memberg SP, Hall AK, Raisman G, Silver J. Regeneration of adult axons in white matter tracts of the central nervous system. Nature 1997;390(6661):680–3.

[22] Li LM, Han M, Jiang XC, Yin XZ, Chen F, Zhang TY, et al. Peptide-tethered hydrogel scaffold promotes recovery from spinal cord transection via synergism with mesenchymal stem cells. ACS Appl Mater Interfaces 2017;9(4):3330–42.

[23] Ducker TB, Kindt GW, Kempf LG. Pathological findings in acute experimental spinal cord trauma. J Neurosurg 1971;35(6):700–8.

[24] Xu J, Kim GM, Chen S, Yan P, Ahmed SH, Ku G, et al. iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma 2001;18(5):523–32.

[25] Satake K, Matsuyama Y, Kamiya M, Kawakami H, Iwata H, Adachi K, et al. Nitric oxide via macrophage iNOS induces apoptosis following traumatic spinal cord injury. Brain Res Mol Brain Res 2000;85(1–2):114–22.

[26] D’Autreaux B, Toledano MB. ROS as signalling molecules: mechanisms that generate specificity in ROS homeostasis. Nat Rev Mol Cell Biol 2007;8(10):813–24.

[27] Bell KF. Insight into a neuron’s preferential susceptibility to oxidative stress. Biochem Soc Trans 2013;41(6):1541–5.

[28] Lidal IB, Snekkevik H, Aamodt G, Hjeltnes N, Biering-Sorensen F, Stanghelle JK. Mortality after spinal cord injury in Norway. J Rehabil Med 2007;39(2):145–51.

[29] Wyndaele JJ. The management of neurogenic lower urinary tract dysfunction after spinal cord injury. Nat Rev Urol 2016;13(12):705–14.

[30] Milligan J, Goetz LL, Kennelly MJ. A primary care provider’s guide to management of neurogenic lower urinary tract dysfunction and urinary tract infection after spinal cord injury. Top Spinal Cord Inj Rehabil 2020;26(2):108–15.

[31] Parent S, Barchi S, LeBreton M, Casha S, Fehlings MG. The impact of specialized centers of care for spinal cord injury on length of stay, complications, and mortality: a systematic review of the literature. J Neurotrauma 2011;28(8):1363–70.